Johnson & Johnson $JNJ Shares Sold by Lansforsakringar Fondforvaltning AB publ

Lansforsakringar Fondforvaltning AB publ lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.8% during the 1st quarter, Holdings Channel reports. The fund owned 791,412 shares of the company’s stock after selling 31,098 shares during the quarter. Johnson & Johnson comprises 1.0% of Lansforsakringar Fondforvaltning AB publ’s portfolio, making the stock its 15th largest holding. Lansforsakringar Fondforvaltning AB publ’s holdings in Johnson & Johnson were worth $193,452,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Blueline Advisors LLC purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $25,000. Cresta Advisors Ltd. purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at approximately $26,000. DecisionPoint Financial LLC lifted its holdings in Johnson & Johnson by 104.2% in the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock valued at $30,000 after acquiring an additional 75 shares during the last quarter. Bay Harbor Wealth Management LLC grew its position in Johnson & Johnson by 49.0% in the fourth quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock worth $31,000 after acquiring an additional 49 shares during the period. Finally, Family CFO Inc acquired a new stake in Johnson & Johnson during the fourth quarter worth $31,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson is strengthening its cancer franchise with positive European regulatory news for Tecvayli in combination with Darzalex SC, plus a planned acquisition of Firefly Bio to expand its oncology pipeline. Johnson & Johnson (JNJ) Expands Cancer Pipeline As Talc Verdict Eases One Risk
• Positive Sentiment: Management reiterated that J&J is prioritizing cancer and neuroscience rather than entering the obesity drug market, which signals a disciplined capital-allocation strategy and a clearer long-term growth plan. Johnson & Johnson (JNJ): Focused on Cancer and Neuroscience as a Top Dividend Aristocrat Stock to Buy
• Positive Sentiment: J&J is being featured by multiple outlets as a top dividend and income stock, and technical commentary says the shares are breaking out past a buy point, which may be encouraging momentum-oriented investors. J&J’s Innovative Medicine Business in Q2: Here’s What to Watch
• Neutral Sentiment: Analysts are focusing on upcoming Q2 Innovative Medicine results, with Stelara biosimilar pressure expected to offset some growth from newer therapies; investors may be waiting for earnings confirmation before pushing the stock higher. J&J’s Innovative Medicine Business in Q2: Here’s What to Watch
• Neutral Sentiment: Recent market coverage notes that J&J has already had a strong one-year rally, so some investors are now weighing whether the valuation still offers upside from here. Johnson & Johnson (JNJ) Stock After 73% One-Year Rally Is There Value Left

Insiders Place Their Bets

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the sale, the executive vice president owned 114,288 shares in the company, valued at approximately $27,560,551.20. The trade was a 8.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Down 0.1%

Shares of NYSE:JNJ opened at $253.76 on Thursday. Johnson & Johnson has a fifty-two week low of $154.21 and a fifty-two week high of $259.90. The firm’s 50 day moving average price is $232.26 and its 200 day moving average price is $230.68. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. The stock has a market cap of $610.86 billion, a price-to-earnings ratio of 29.34, a price-to-earnings-growth ratio of 2.49 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The company had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. During the same period in the previous year, the business earned $2.77 EPS. Johnson & Johnson’s revenue for the quarter was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were paid a $1.34 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 annualized dividend and a yield of 2.1%. The ex-dividend date was Tuesday, May 26th. Johnson & Johnson’s payout ratio is currently 61.97%.

Analyst Upgrades and Downgrades

JNJ has been the topic of several recent analyst reports. Stifel Nicolaus upped their price target on Johnson & Johnson from $220.00 to $250.00 and gave the company a “hold” rating in a research note on Wednesday, April 15th. Guggenheim boosted their price objective on shares of Johnson & Johnson from $266.00 to $270.00 and gave the company a “buy” rating in a report on Friday, June 26th. Morgan Stanley set a $283.00 target price on shares of Johnson & Johnson in a research report on Wednesday, April 15th. Leerink Partners raised shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 target price for the company in a research note on Wednesday, May 13th. Finally, TD Cowen assumed coverage on shares of Johnson & Johnson in a research report on Wednesday, April 8th. They set a “buy” rating and a $250.00 price target for the company. Twenty research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $256.70.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.